Atea Pharmaceuticals (AVIR) Insider Lucidi Sells 29,600 Shares

Bruno Lucidi Trades AVIR Shares

On June 18, 2026, Bruno Lucidi disposed of 29,600 shares of Atea Pharmaceuticals, Inc. (NasdaqGS: AVIR). Insider transactions like this one offer a window into how people closely tied to a business manage their personal holdings, though sales do not automatically signal a negative outlook for the enterprise.

A Busy Day of Insider Transactions

The transaction occurred alongside several other moves by people connected to the biotechnology firm on the exact same day. Bruce Polsky acquired 29,600 shares on June 18, 2026. Franklin Berger also was active, picking up 29,600 shares and separately selling 29,600 shares on that date. Polly Murphy sold 29,600 shares of the company on June 18, 2026. In addition, Howard Berman purchased 37,700 shares of AVIR on June 18, 2026, adding further context to the day's corporate activity.

Stock Performance and Recent Levels

Shares of Atea Pharmaceuticals trade on the NasdaqGS under the ticker AVIR. The stock changes hands against a backdrop where the company carries a market capitalization of roughly $434.5 million. The equity moves within a 52-week range that extends from a low of $2.78 up to a high of $6.45.

Analysts Set New Price Targets

Wall Street firms continue to evaluate the clinical-stage biotech firm. On August 13, 2026, Morgan Stanley maintained its Equal-Weight rating on AVIR while adjusting its price target to $7.00 from a previous target of $6.00. Across the broader analyst community, the stock holds a consensus target mean price of $9.42 based on three analyst opinions, with high and low targets set at $11.25 and $7.00 respectively.

Inside Atea Pharmaceuticals Operations

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm based in Boston, Massachusetts, that focuses on discovering and developing oral antiviral medicines for serious viral infections. Its lead treatment regimen combines bemnifosbuvir and ruzasvir for hepatitis C, and the company also works on candidates for chronic HEV infections using its proprietary nucleotide platform.

Looking Ahead for Investors

Investors tracking the biotechnology company can look ahead to its next scheduled earnings report on November 11, 2026, for further updates on its clinical trials and financial standing. Insider trades reflect individual choices by executives and board members, and market participants will watch for subsequent Form 4 filings to see how ownership patterns evolve.